Sep 04, 2024 9:00am EDT Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 13, 2024 8:00am EDT Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 15, 2024 8:30am EDT Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Jul 03, 2024 9:00am EDT Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Jul 02, 2024 9:00am EDT Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
Jul 01, 2024 9:00am EDT Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
Jun 04, 2024 8:30am EDT Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
May 29, 2024 8:30am EDT Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
May 13, 2024 8:00am EDT Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024 9:00am EDT Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
